[RAAS inhibitors as therapeutic alternatives in the treatment of chronic liver diseases].
Recent studies have shown that RAAS plays a pivotal role in the progression of chronic liver diseases, i.e., liver fibrosis and hepatocellular carcinoma (HCC). Many studies have demonstrated that the clinically used angiotensin-converting enzyme inhibitor (ACE I), and AT1-R blockers (ARB) significantly attenuated the liver fibrosis development and HCC. The combined treatment of ACE-I with other clinically used agents, such as interferon, imatinib mesylate, and vitamin K shows more potent inhibitory effects on the development of liver fibrosis and HCC. Since RAAS inhibitors are widely used in the clinical practice without serious side effects, they may represent a potential new therapeutic strategy against the progression of chronic liver diseases.
Yoshiji
Hitoshi
H
Third Department of Internal Medicine, Nara Medical University.
Noguchi
Ryuichi
R
Fukui
Hiroshi
H
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002908:Chronic Disease; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors